National drug policies to local formulary decisions in Thailand, China, and Australia: Drug listing changes and opportunities

Worasuda Yoongthong, Shanlian Hu, Jennifer A. Whitty, Suwit Wibulpolprasert, Kitti Sukantho, Wannisa Thienthawee, Huixue Han, Paul A. Scuffham

Research output: Contribution to journalArticlepeer-review

28 Citations (Scopus)


This commentary is aimed at summarizing the second plenary session presented at the ISPOR 4th Asia-Pacific Conference held in 2010 and compare the issues on drug listing of Thailand, China, and Australia. These countries have substantially different demographic and economic characteristics and health-care financing structures and are in different phases of development of health technology assessment (HTA) (Table 1). Expenditure data shown in Table 1 for 2008 were converted at purchasing power parity to US dollars.
Original languageEnglish
Pages (from-to)S126-S131
Number of pages6
JournalValue in Health
Issue number1
Publication statusPublished - Jan 2012

Cite this